CRISPR Therapeutics(CRSP) - 2023 Q4 - Annual Results

Exhibit 99.1 CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results — CASGEVY™ approved in the U.S., European Union, Great Britain, the Kingdom of Saudi Arabia and Bahrain — — Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70, respectively – — Clinical trials ongoing for in vivo gene editing product candidates, CTX310™ and CTX320™ targeting ANGPTL3 and Lp(a), respectively — — Clinical trial ...